Lilly's injectable advantage over Novo
The case was made that Eli Lilly's injectable drugs (Zepbound/Mounjaro) have a clinical profile advantage over Novo Nordisk's due to targeting two pathways (GLP-1 and GIP) versus one.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.